Humacyte (HUMA) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Humacyte will report Q1 2026 results before the market opens on Tuesday, May 12 (call at 8:30 AM ET); analysts expect ($0.10) EPS and $1.464 million in revenue.
• In the prior quarter Humacyte posted ($0.13) EPS (matching estimates) but revenue missed at $0.47 million versus $1.35 million expected, and the company reported very large negative net margin and return on equity.
• Shares were down 4.8% at $0.88 with a market cap of about $195 million; analyst coverage is mixed but the consensus rating is "Moderate Buy" with a $7.71 target and institutional ownership near 44.7%.

Humacyte (NASDAQ:HUMA - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.4640 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $0.47 million for the quarter, compared to analysts' expectations of $1.35 million. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%. On average, analysts expect Humacyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Humacyte Stock Down 4.8%

Shares of HUMA traded down $0.04 during mid-day trading on Tuesday, hitting $0.88. 2,102,128 shares of the company's stock were exchanged, compared to its average volume of 6,233,893. The company has a market cap of $195.38 million, a price-to-earnings ratio of -4.40 and a beta of 2.31. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The company has a debt-to-equity ratio of 20.08, a quick ratio of 2.95 and a current ratio of 3.69. The stock's 50-day moving average is $0.88 and its 200-day moving average is $1.10.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HUMA. Wall Street Zen cut shares of Humacyte from a "sell" rating to a "strong sell" rating in a report on Saturday, April 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Benchmark reduced their target price on shares of Humacyte from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, January 21st. BTIG Research reaffirmed a "buy" rating and issued a $3.00 target price on shares of Humacyte in a report on Tuesday, April 28th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a report on Friday, April 10th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.71.

Hedge Funds Weigh In On Humacyte

Hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. purchased a new position in Humacyte in the second quarter valued at approximately $28,000. Financial Advisors Network Inc. purchased a new position in Humacyte in the second quarter valued at approximately $28,000. Cerity Partners LLC purchased a new position in Humacyte in the second quarter valued at approximately $35,000. Equitable Holdings Inc. purchased a new position in Humacyte in the third quarter valued at approximately $29,000. Finally, Imprint Wealth LLC purchased a new position in Humacyte in the third quarter valued at approximately $33,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.